Work

Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.6_suppl.447

Authors: Steven Lacy, Matthew M Hutmacher, Bei Yang, Robert J. Motzer, Bernard J. Escudier, Thomas Powles, Toni K. Choueiri, Jace Nielsen

Institutions: Exelixis (United States), Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Queen Mary University of London, Barts Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602809318

Cites:

Cited by: 2

Related to: 10